Your search has found 291 articles in the database for the term 'Cognition'
Click
here to filter this large number of results.
Efficacy of a cognitive training programme for mild cognitive impairment: Results of a randomised controlled study
Jean, Léonie,
Simard, Martine,
Wiederkehr, Sandra,
Bergeron, Marie-Ève,
Turgeon, Yves,
Hudon, Carol,
Tremblay, Isabelle,
van Reekum, Robert
This study aimed to determine the efficacy of cognitive training in a 10-week randomised controlled study involving 22 individuals presenting with mild cognitive impairment of the amnestic type...
Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study
Ikeda, Manabu,
Mori, Etsuro,
Kosaka, Kenji,
Iseki, Eizo,
Hashimoto, Mamoru,
Matsukawa, Noriyuki,
Matsuo, Kazutaka,
Nakagawa, Masaki
Background/aims: To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB).; Methods: This was a 52-week, multicenter,...
Cilostazol add-on therapy in patients with mild dementia receiving donepezil: A retrospective study
Ihara, Masafumi,
Nishino, Madoka,
Taguchi, Akihiko,
Yamamoto, Yumi,
Hattori, Yorito,
Saito, Satoshi,
Takahashi, Yukako,
Tsuji, Masahiro,
Kasahara, Yukiko,
Takata, Yu,
Okada, Masahiro
Goal: Combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia may offer a promising strategy for treatment of dementia, which often has a multifactorial basis in...
Memantine effects measured with the Relevant Outcome Scale for Alzheimer’s disease in an open-label, single-arm, multicenter clinical study
Holthoff, Vjera,
Ferris, Steven,
Gauthier, Serge,
Ihl, Ralf,
Robert, Philippe,
Winblad, Bengt,
Sternberg, Kati,
Tennigkeit, Frank
Objective: The Relevant Outcome Scale for Alzheimer’s disease (ROSA) is a novel, valid, and reliable instrument for multidimensional assessment of Alzheimer’s disease (AD) symptoms across all severity stages....
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors
Grossberg, George T.,
Manes, Facundo,
Allegri, Ricardo F.,
Gutiérrez-Robledo, Luis Miguel,
Gloger, Sergio,
Xie, Lei,
Jia, X. Daniel,
Pejović, Vojislav,
Miller, Michael L.,
Perhach, James L.,
Graham, Stephen M.
Introduction: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose,...
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease
Grossberg, G.,
Cummings, J.,
Frolich, L.,
Bellelli, G.,
Molinuevo, J. L.,
Krahnke, T.,
Strohmaier, C.
Background: Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer’s disease (AD).; Methods: Post hoc analysis of OPtimizing Transdermal...
A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects
Grimaldi, Luigi Maria,
Zappalà, Giuseppe,
Iemolo, Francesco,
Castellano, Anna,
Ruggieri, Stefano,
Bruno, Giuseppe,
Paolillo, Andrea
Despite the fact that multiple sclerosis (MS) and Alzheimer’s disease (AD) share common neuroimmunological features, interferon beta 1a (IFNβ1a), the well-established treatment for the prevention of disease progression...
Semantic memory training in Alzheimer’s disease
The purpose of this study was to assess the effects of semantic stimulation of Alzheimer’s patients on semantic memory comparatively to psychological support. We conducted semantic training with...